Company intelligence / Profile preview
Takata Pharmaceutical
- Ownership
- Private
- Employees
- ~790
- Development stage
- Other
Overview
Takata Pharmaceutical is a generics-focused pharmaceutical company with approved drugs in Japan, including products for infectious, metabolic, nervous, immune diseases, and oncology. Notably, it is assuming marketing authorization for Elplat (oxaliplatin) for use in gastric and small intestine cancers in Japan.[7][8]
- Therapeutic areas
- ImmunologyEndocrinologyInfectious DiseasesGastroenterologyOncologyNeurology
- Modalities
- Small moleculeHerbal medicineEnzymeChemical drugs
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Takata Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Takata Pharmaceutical.